The Pulse
ByteDance’s Anew Labs Raises $290 Million in First Outside Round
ByteDance’s spun-out drug discovery company Anew Labs has raised $290 million at a $1.5 billion valuation. HSG, IDG Capital, Hillhouse Investment and 5Y Capital led the round while ByteDance retained a 56% stake.
AI.info Team ·
ByteDance has separated its drug-discovery operation from the rest of the company, but it is not giving up control. Anew Labs, the Shanghai-based company formed from ByteDance’s internal AI drug unit, has closed a $290 million first external funding round at a $1.5 billion valuation, according to TechFlier.
ByteDance retains a 56% stake after the financing. The arrangement gives Anew access to outside investors and a standalone corporate structure while keeping the business under ByteDance’s majority ownership.
A $290 Million Round With ByteDance Still in Control
HSG, the investment firm formerly known as Sequoia China, led the round alongside IDG Capital and Hillhouse Investment. 5Y Capital served as a co-lead investor. Gaorong Ventures, Primavera Venture Partners, Boyu Capital, strategic investor SBP Group and the state-backed Shanghai Future Industries Fund also participated, TechFlier reported.
ByteDance and the investors declined to comment on the transaction. The reported valuation places Anew among the most heavily financed Chinese companies focused on AI-assisted drug discovery, although the company has not publicly disclosed the individual investment amounts or the terms assigned to each backer.
Why ByteDance Spun Out the Drug Unit
The separation reflects a mismatch between drug development and ByteDance’s main internet businesses. Drug discovery requires extended experimental work, regulatory planning and substantial spending before a product can reach the market. Sources cited by TechFlier said the unit was separated because AI drug discovery follows different operating and management requirements from ByteDance’s core operations.
A standalone company can raise capital directly from biotechnology and venture investors, form pharmaceutical partnerships and manage a research pipeline on a timetable distinct from ByteDance’s consumer platforms. ByteDance’s majority position also lets it retain influence over the technology and programs developed inside the group.
Anew’s Models Cover Proteins, Molecules and Antibodies
Anew Labs’ website describes a platform built around biomolecular structure prediction, molecular dynamics, molecular design and antibody engineering. Its named systems include AnewFold for protein and molecular-complex structure prediction, AnewSampling for dynamics-aware modeling, AnewOmni for all-atom generative modeling and AnewDesign for antibody design and optimization.
The company also lists AnewMind, a scientific-reasoning language model aimed at drug-discovery decisions. On September 17, 2026, Anew published a technical report for AnewDDE, which it describes as an agentic drug-discovery engine combining structure prediction, molecular design, binding-affinity analysis and scientific reasoning with experimental feedback.
The website lists four pipeline programs: IL17AA/AF/FF, IL4R and two undisclosed targets. Anew says its integrated platform is intended to support work from target identification through hit discovery, lead optimization and investigational new drug preparation.
The Company’s Next Test Is Experimental Validation
Anew’s financing arrives as investors continue to back companies that apply machine learning to early-stage pharmaceutical research. The funding does not establish that any of the company’s programs will produce an approved medicine. It gives Anew the resources to test whether its models can produce candidates that survive laboratory experiments and the later stages of drug development.
The company operates from Shanghai, with additional offices in San Francisco and Singapore, according to its website. Its immediate challenge is to turn the computational systems inherited from ByteDance into validated drug programs while managing the slower, more capital-intensive work that prompted the spin-out in the first place.